Reumatoloxía e Enfermidades Inmuno-mediadas ‘IRIDIS’
![Foto de Reumatoloxía e Enfermidades Inmuno-mediadas ‘IRIDIS’](/img/grupo.png)
![Foto de Hospital Universitario Marqués de Valdecilla](/img/noimage_org.png)
Hospital Universitario Marqués de Valdecilla
Santander, EspañaPublicacións en colaboración con investigadores/as de Hospital Universitario Marqués de Valdecilla (45)
2024
-
SLESIS-R: an improved score for prediction of serious infection in patients with systemic lupus erythematosus based on the RELESSER prospective cohort
Lupus Science and Medicine, Vol. 11, Núm. 1
-
Subcutaneous vs intravenous abatacept in rheumatoid arthritis-interstitial lung disease. National multicentre study of 397 patients
Seminars in Arthritis and Rheumatism, Vol. 68
2023
-
A second update on mapping the human genetic architecture of COVID-19
Nature
-
Abatacept in usual and in non-specific interstitial pneumonia associated with rheumatoid arthritis
European Journal of Internal Medicine
-
Central nervous system involvement in systemic lupus erythematosus: Data from the Spanish Society of Rheumatology Lupus Register (RELESSER)
Seminars in Arthritis and Rheumatism, Vol. 58
-
Immunoglobulins in systemic sclerosis management. A large multicenter experience
Autoimmunity Reviews, Vol. 22, Núm. 11
-
Pregnancy outcomes in 1869 pregnancies in a large cohort from the Spanish Society of Rheumatology Lupus Register (RELESSER)
Seminars in Arthritis and Rheumatism, Vol. 61
2022
-
Antimalarials exert a cardioprotective effect in lupus patients: Insights from the Spanish Society of Rheumatology Lupus Register (RELESSER) analysis of factors associated with heart failure
Seminars in Arthritis and Rheumatism, Vol. 52
-
Biologic therapy in refractory neurobehçet's disease: a multicentre study of 41 patients and literature review
Rheumatology (Oxford, England), Vol. 61, Núm. 11, pp. 4427-4436
-
Novel genes and sex differences in COVID-19 severity
Human molecular genetics, Vol. 31, Núm. 22, pp. 3789-3806
2021
-
Do all antiphospholipid antibodies confer the same risk for major organ involvement in systemic lupus erythematosus patients?
Clinical and Experimental Rheumatology, Vol. 39, Núm. 3, pp. 555-563
-
Relevance of gastrointestinal manifestations in a large Spanish cohort of patients with systemic lupus erythematosus: what do we know?
Rheumatology (Oxford, England), Vol. 60, Núm. 11, pp. 5329-5336
-
Role of MUC1 rs4072037 polymorphism and serum KL-6 levels in patients with antisynthetase syndrome
Scientific Reports, Vol. 11, Núm. 1
-
Role of targeted therapies in rheumatic patients on COVID-19 outcomes: Results from the COVIDSER study
RMD Open, Vol. 7, Núm. 3
-
Treatment with tofacitinib in refractory psoriatic arthritis: A national multicenter study of the first 87 patients in clinical practice
Journal of Rheumatology, Vol. 48, Núm. 10, pp. 1552-1558
2020
-
Antiphospholipid syndrome (APS) in patients with systemic lupus erythematosus (SLE) implies a more severe disease with more damage accrual and higher mortality
Lupus, Vol. 29, Núm. 12, pp. 1556-1565
-
Associated factors to serious infections in a large cohort of juvenile-onset systemic lupus erythematosus from Lupus Registry (RELESSER).
Seminars in Arthritis and Rheumatism, Vol. 50, Núm. 4, pp. 657-662
-
Clinical features and outcomes of COVID-19 in patients with rheumatic diseases treated with biological and synthetic targeted therapies
Annals of the Rheumatic Diseases
-
Development of an application for mobile phones (App) based on the collaboration between the Spanish Society of Rheumatology and Spanish Society of Family Medicine for the referral of systemic autoimmune diseases from primary care to rheumatology
Reumatologia Clinica, Vol. 16, Núm. 5, pp. 373-377
-
Differences in clinical manifestations and increased severity of systemic lupus erythematosus between two groups of Hispanics: European Caucasians versus Latin American mestizos (data from the RELESSER registry)
Lupus, Vol. 29, Núm. 1, pp. 27-36